Autoimmune Pulmonary Alveolar Proteinosis Clinical Trial
Official title:
An Open-label Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of hBMMSC Injection in the Treatment of aPAP
The purpose of this open-label phase IIa clinical trial study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP.
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease for which there is no specific drug treatment. Currently, the standard treatment strategy for PAP is whole-lung lavage (WLL), which is invasive and has limited therapeutic efficacy. The purpose of this study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP. The clinical trial intends to involve 10 participants. The trial is expected to last approximately 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04544293 -
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
Phase 3 | |
| Completed |
NCT02702180 -
Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
|
Phase 2 | |
| Completed |
NCT00901511 -
Inhaled GM-CSF Therapy of Autoimmune PAP
|
Phase 2 | |
| Completed |
NCT03006146 -
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
|
Phase 1 | |
| Recruiting |
NCT02243228 -
Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
|
Phase 2 | |
| Completed |
NCT03231033 -
Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
|
Phase 1 | |
| Completed |
NCT03531996 -
The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
|
||
| Completed |
NCT03482752 -
Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
|
Phase 3 |